Active — Not RecruitingNot Applicable

Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

Canada502 participantsStarted 2018-08-24

Plain-language summary

A multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial low voltage area mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients with persistent atrial fibrillation (AF).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years;
✓. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF;
✓. Persistent AF defined as a sustained episode beyond 3 months in duration;
✓. At least one episode of AF must have been documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study;
✓. Modified DR-FLASH score \>=3

Exclusion criteria

✕. History of previous catheter ablation for AF or left atrial flutter;
✕. History of previous surgical ablation for AF;
✕. Known intracardiac thrombus;
✕. Contraindication to systemic oral anticoagulation therapy;
✕. Reversible causes of AF;
✕. Hypertrophic cardiomyopathy;
✕. Severe valvular disease (mitral/aortic stenosis or regurgitation);
✕. Subjects that are pregnant or breastfeeding;

What they're measuring

Rate of documented (>30s) AF, atrial flutter or atrial tachycardia occuring from day 91 to 18 months post ablation

Timeframe: day 91 post ablation to 18 months

Trial details

NCT IDNCT03347227

SponsorOttawa Heart Institute Research Corporation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-23

View on ClinicalTrials.gov More Atrial Fibrillation trials